Mark Your Calendar to Join Us Next Year September 23-26, 2024
Boston Convention and Exhibition CenterBoston, MAkeyboard_arrow_right
Search & Filter keyboard_arrow_right
keyboard_arrow_left Hide
Main Conference - Day 2 - EST/EDT (Eastern Daylight, GMT-4)
keyboard_arrow_leftSearch & Filter
search
Streams
Main Conference - Day 2 - EST/EDT (Eastern Daylight, GMT-4)
search
Streams
6:30am - 7:30am
Attendee 5k Fun Run - Registration Desk @ Boston Convention & Exhibition Center Main Lobby
Start off your day with a fun run around Boston’s Beautiful Seaport! This 5k run will be led by our marathon running staff. We will meet at the registration desk at the Boston Convention & Exhibition Center, run past some of Boston’s magnificent landmarks and see some of the most beautiful views of the skyline. You will also receive a BWB T-Shirt for your participation. (subject to availability so come early before they run out)
RSVP FOR THE FUN RUN
7:30am - 8:00am
Breakfast and Registration
Showing 9 of 9 Streams
Cell Culture & Upstream Processing - Room 210C
Recovery & Purification - Room 210B
Manufacturing Strategy & Bioprocessing 4.0 - Room 210A
Analytical & Quality - Room 209
Well Characterized Biologics & Biological Assays - Room 208
Cell Therapy Manufacturing - Room 206AB
Gene Edited Ex Vivo Manufacturing - Room 205C
In Vivo Gene Therapy Manufacturing - Room 205AB
BWB Main Stage
8:00am - 8:10am
Chairperson’s Remarks
- Vilas B Shukla, Ph.D., PMP - Global Senior Principal Engineer, Biologics, AbbVie Operations
8:10am - 8:50am
Digital Transformation: Keys to achieving breakthrough transformation of Manufacturing & Supply Operations
- Janani Swamy - Head of Operational Excellence and Digital Transformation, Sanofi
8:50am - 9:30am
Innovative strategies and technologies to drive sustainability of Biologics Process Development
- David Roush, Ph.D. - Distinguished Scientist, Merck
- Sri Madabhushi - Principal Scientist, Merck & Co., Inc.
8:00am - 8:10am
Chairperson’s Remarks
- Vilas B Shukla, Ph.D., PMP - Global Senior Principal Engineer, Biologics, AbbVie Operations
8:10am - 8:50am
Digital Transformation: Keys to achieving breakthrough transformation of Manufacturing & Supply Operations
- Janani Swamy - Head of Operational Excellence and Digital Transformation, Sanofi
8:50am - 9:30am
Innovative strategies and technologies to drive sustainability of Biologics Process Development
- David Roush, Ph.D. - Distinguished Scientist, Merck
- Sri Madabhushi - Principal Scientist, Merck & Co., Inc.
8:00am - 8:10am
Chairperson’s Remarks
- Vilas B Shukla, Ph.D., PMP - Global Senior Principal Engineer, Biologics, AbbVie Operations
8:10am - 8:50am
Digital Transformation: Keys to achieving breakthrough transformation of Manufacturing & Supply Operations
- Janani Swamy - Head of Operational Excellence and Digital Transformation, Sanofi
8:50am - 9:30am
Innovative strategies and technologies to drive sustainability of Biologics Process Development
- David Roush, Ph.D. - Distinguished Scientist, Merck
- Sri Madabhushi - Principal Scientist, Merck & Co., Inc.
8:00am - 8:10am
Chairperson’s Remarks
- Vilas B Shukla, Ph.D., PMP - Global Senior Principal Engineer, Biologics, AbbVie Operations
8:10am - 8:50am
Digital Transformation: Keys to achieving breakthrough transformation of Manufacturing & Supply Operations
- Janani Swamy - Head of Operational Excellence and Digital Transformation, Sanofi
8:50am - 9:30am
Innovative strategies and technologies to drive sustainability of Biologics Process Development
- David Roush, Ph.D. - Distinguished Scientist, Merck
- Sri Madabhushi - Principal Scientist, Merck & Co., Inc.
8:00am - 8:10am
Chairperson’s Remarks
- Vilas B Shukla, Ph.D., PMP - Global Senior Principal Engineer, Biologics, AbbVie Operations
8:10am - 8:50am
Digital Transformation: Keys to achieving breakthrough transformation of Manufacturing & Supply Operations
- Janani Swamy - Head of Operational Excellence and Digital Transformation, Sanofi
8:50am - 9:30am
Innovative strategies and technologies to drive sustainability of Biologics Process Development
- David Roush, Ph.D. - Distinguished Scientist, Merck
- Sri Madabhushi - Principal Scientist, Merck & Co., Inc.
8:00am - 8:10am
Chairperson’s Remarks
- Vilas B Shukla, Ph.D., PMP - Global Senior Principal Engineer, Biologics, AbbVie Operations
8:10am - 8:50am
Digital Transformation: Keys to achieving breakthrough transformation of Manufacturing & Supply Operations
- Janani Swamy - Head of Operational Excellence and Digital Transformation, Sanofi
8:50am - 9:30am
Innovative strategies and technologies to drive sustainability of Biologics Process Development
- David Roush, Ph.D. - Distinguished Scientist, Merck
- Sri Madabhushi - Principal Scientist, Merck & Co., Inc.
8:00am - 8:10am
Chairperson’s Remarks
- Vilas B Shukla, Ph.D., PMP - Global Senior Principal Engineer, Biologics, AbbVie Operations
8:10am - 8:50am
Digital Transformation: Keys to achieving breakthrough transformation of Manufacturing & Supply Operations
- Janani Swamy - Head of Operational Excellence and Digital Transformation, Sanofi
8:50am - 9:30am
Innovative strategies and technologies to drive sustainability of Biologics Process Development
- David Roush, Ph.D. - Distinguished Scientist, Merck
- Sri Madabhushi - Principal Scientist, Merck & Co., Inc.
8:00am - 8:10am
Chairperson’s Remarks
- Vilas B Shukla, Ph.D., PMP - Global Senior Principal Engineer, Biologics, AbbVie Operations
8:10am - 8:50am
Digital Transformation: Keys to achieving breakthrough transformation of Manufacturing & Supply Operations
- Janani Swamy - Head of Operational Excellence and Digital Transformation, Sanofi
8:50am - 9:30am
Innovative strategies and technologies to drive sustainability of Biologics Process Development
- David Roush, Ph.D. - Distinguished Scientist, Merck
- Sri Madabhushi - Principal Scientist, Merck & Co., Inc.
9:20am - 9:30am
Chairpersons Opening Remarks
- Willis Thomas - HR Business Partner, PQE
Showing 2 of 2 Streams
Break
BWB Main Stage
9:30am - 10:25am
Morning Break in the Exhibit & Poster Hall
9:30am - 9:40am
High-volume Fluid Transfer
- Michael Francis - Product Manager, CPC - Colder Products Company
9:40am - 9:50am
Integrated Sensors for Smart Biopharma Peristatic Pump Systems
- Aaron Schneider - Product Manager, Avantor
9:50am - 10:10am
C1 Gene Expression Platform: Rapid, High Yield and Lower Cost Way to Develop and Manufacture Biologics
- Joseph Hazelton - Chief Business Officer, Dyadic
10:15am - 10:25am
[10:15-11:50] Innovation Start Up Showcase
- Lynne Frick - CEO, Cell X Technologies, Inc. & Co-Executive Director, BioInnovation Group, BioGuides LLC & BioInnovation Group
- Gregg Nyberg - Chief Technology Officer, Landmark Bio
- Sarah Yuan - Chief Technical Operations Officer, Sigilon Therapeutics: A wholly owned subsidiary of Eli Lilly and Company
- Dmitry Gumerov - Director, CMC Pharmaceutical Sciences and Technology, Visterra Inc
- Carrie Mason - Associate Director Biologics R&D a PAT/Automation, Lonza
- Joseph Shultz - Vice President & Technical Head of Biologics and Vaccines, Resilience
- Jason Criscione - CSO and Member, Board of Directors, Enquyst Technologies Inc.
- Mandana Manzari Honu - Head of Business Development, Kaleidoscope
- Caroline Johnson - Application Scientist, Cell X Technologies, Inc
- Marcie Black - CEO and Co-Founder, Advanced Silicon Group
- Irene Rombel - Co-Founder and CEO, BioCurie
Showing 9 of 9 Streams
Cell Culture & Upstream Processing - Room 210C
Recovery & Purification - Room 210B
Manufacturing Strategy & Bioprocessing 4.0 - Room 210A
Analytical & Quality - Room 209
Well Characterized Biologics & Biological Assays - Room 208
Cell Therapy Manufacturing - Room 206AB
Gene Edited Ex Vivo Manufacturing - Room 205C
In Vivo Gene Therapy Manufacturing - Room 205AB
BWB Main Stage
10:25am - 10:30am
Chairperson's Opening Remarks
- Christian Witz - CEO, SimVantage
10:30am - 11:00am
A Practical Approach to Predict Carbon Di-oxide Partial Pressure During Scale-up and Tech Transfer of Mammalian Cell Culture in Manufacturing Scale Bioreactors
- Abdullah Al Loman - Senior Engineer II, Technical Development, Biogen
11:00am - 11:30am
Characterization of Early Seed Cultures to Enable Process Comparability Between Scales
- Cindy Chelius, Ph.D. - Senior Scientist, Upstream Bioprocess Development, Global Product Development & Supply, Bristol Myers Squibb
11:30am - 12:00pm
The technology debate: Single-use vs. stainless steel
- Natraj Ram - Vice President, Innovation, Bioproduction, ThermoFisher Scientific
- Merrilyn Datta - Vice President, Global Marketing and Strategy, Bioproduction, Thermo Fisher Scientific
10:25am - 10:30am
Chairperson's Opening Remarks
- Leslie Wolfe, PhD - Vice President, Process Development, KBI Biopharma
10:30am - 11:00am
What’s Old Is New – Continuous Countercurrent Staging for Chromatographic Separations and Precipitation
- Andrew Zydney, Ph.D. - Bayard D. Kunkle Chair, Chemical Engineering, Penn State University
11:00am - 11:30am
Transitioning from Batch to Fully Continuous Bioprocessing; Considerations for Process Development and Implementation
- Akshat Mullerpatan, Ph.D. - Scientist, Purification Process Development, Sanofi
11:30am - 12:00pm
Evaluating the Effects of Pressure Fluctuation on Viral Clearance of Planova™ 20N and BioEX Filters
- Katherine Powers - Senior Field Applications Specialist, Asahi Kasei Bioprocess America
10:25am - 10:30am
Chairperson's Opening Remarks
- Dhanuka Wasalathanthri, PhD - Senior Principal Scientist, Bristol Myers Squibb
10:30am - 11:00am
PAT to facilitate monitoring and control of continuous bioprocessing
- Boyong Wan - Associate Principal Scientist, Merck
11:00am - 11:30am
Gearing toward BioProcessing 4.0 through Enabling Technology Development
- Nandkishor Nere - Director, Pharm. Dev./ACoS Research Fellow, Abbvie
11:30am - 12:00pm
Delivering Fast, Flexible, Reliable Process Development and Manufacturing Leveraging Digital Technologies
- Kristen Manchester - Director, BioProcess Integrated PD, Cytiva
10:25am - 10:30am
Chairperson's Opening Remarks
- Anirban Adhikari - Global Technical & CMC Director (Analytical Development), Lonza
10:30am - 11:00am
Implementation of Multi-Attribute Methods
- Da Ren - Founder and CEO, BioTherapeutics Solutions
11:00am - 11:30am
Benefits of Multi-Attribute Methods in QC Laboratory Setting
- Jonathan Bones, Ph.D. - Principal Investigator, NIBRT Characterization and Comparability Laboratory, National Institute for Bioprocessing Research & Training (NIBRT)
11:30am - 12:00pm
Raman technology to enable real-time upstream bioprocess monitoring and continuous control: From media preparation to cell culture expansion
- Lee Asplund - PAT Analytical Sales Consultant, MilliporeSigma
10:25am - 10:30am
Chairperson's Opening Remarks
- Nadine Ritter, Ph.D. - President and Analytical Advisor, Global Biotech Experts, LLC
10:30am - 11:00am
ORSI Extramural Programs (BAA & CERSI)
- Shaila Shaheed - Supervisory Analytics Officer/Program Manager, U.S. Food and Drug Administration (FDA)
11:00am - 11:30am
Connecting the dots - How to connect primary and working reference standards when your therapeutic is a cellular (CAR T) product
- Michael Sadick, Ph.D. - Senior Director, Imugene
11:30am - 12:00pm
De-risking the Development of Tomorrow’s Medicines with Advancing Analytical Characterization Capabilities
- Jason Barker - Director of Analytical Development, Analytical Method Transfer, and Formulation Development, FUJIFILM Diosynth Biotechnologies
10:25am - 10:30am
Chairperson's Opening Remarks
- Amish Patel - SVP Technical Operations, Calidi Biotherapeutics
10:30am - 11:00am
Considerations for the Introduction of New Raw Materials to a Clinical Cell Therapy Process
- Erhan Selvi - Senior Engineer, Bristol Myers Squibb
11:00am - 11:30am
Raw Material Considerations for Cell and Gene Therapy Manufacturing
- Greg Walsh - Associate Director CMSC-MSAT, Vertex
11:30am - 12:00pm
How the Biological, Physiochemical and Regulatory Features of Recombinant Human Albumin Can Ease the Journey to Market for Your Advanced Therapy
- Phil Morton - Chief Technology Officer, Albumedix
10:25am - 10:30am
Chairperson's Opening Remarks
10:30am - 11:00am
Drug Product Development of an Allogeneic NK-Cell Therapy
- Randall Mauldin - Associate Director, Biologics Drug Product Department, Sanofi
11:00am - 11:30am
Manufacturing Gene Edited Immune Cells using TcBuster™ transposase system
- Ariel Miller - Supervisor CGT Applications, Bio-Techne
10:25am - 10:30am
Chairperson's Opening Remarks
- Tim McClain - North American Sales Manager, c-LEcta GmbH (Part of Kerry Group)
10:30am - 10:50am
Improvements and Innovations in Cell Line Development & Engineering to Increase Yields for Gene Therapies
- Alix Eastham - Sr Manager Cell Line Dev, Ultragenyx Pharmaceuticals Gene Therapy
10:50am - 11:10am
Establishment of a Process Development Workflow to Support Inducible Producer Cell Line (iPCL) Development for AAV Production
- Dan Odenwelder - Senior Engineer III, Biogen
11:10am - 11:30am
Next-Gen Plasmid Design mAAVRx Achieves High-Yield, High-Quality And Potent AAV Vectors In Scalable Suspension Hek293 Cells
- Jing Liao - Director of Vector Development and Operations, Alexion Pharmaceuticals
11:30am - 12:00pm
Strategic Considerations for Viral Vector Platforms
- Ian Goodwin - Director, Program Design, Fujifilm Diosynth Biotechnologies
10:25am - 11:50am
[10:15-11:50] Innovation Start Up Showcase
- Lynne Frick - CEO, Cell X Technologies, Inc. & Co-Executive Director, BioInnovation Group, BioGuides LLC & BioInnovation Group
- Gregg Nyberg - Chief Technology Officer, Landmark Bio
- Sarah Yuan - Chief Technical Operations Officer, Sigilon Therapeutics: A wholly owned subsidiary of Eli Lilly and Company
- Dmitry Gumerov - Director, CMC Pharmaceutical Sciences and Technology, Visterra Inc
- Carrie Mason - Associate Director Biologics R&D a PAT/Automation, Lonza
- Joseph Shultz - Vice President & Technical Head of Biologics and Vaccines, Resilience
- Jason Criscione - CSO and Member, Board of Directors, Enquyst Technologies Inc.
- Mandana Manzari Honu - Head of Business Development, Kaleidoscope
- Caroline Johnson - Application Scientist, Cell X Technologies, Inc
- Marcie Black - CEO and Co-Founder, Advanced Silicon Group
- Irene Rombel - Co-Founder and CEO, BioCurie
11:50am - 11:55am
Break
11:55am - 12:00pm
[11:55-12:15] Characterization and Quantification of Adeno-associated Virus Fill States Using Analytical Ultracentrifugation
- N. Karl Maluf - Director of the Biophysical Characterization Core, KBI Biopharma
Showing 2 of 2 Streams
Break
BWB Main Stage
12:00pm - 1:25pm
Lunch in the Exhibit & Poster Hall
12:00pm - 12:15pm
[11:55-12:15] Characterization and Quantification of Adeno-associated Virus Fill States Using Analytical Ultracentrifugation
- N. Karl Maluf - Director of the Biophysical Characterization Core, KBI Biopharma
12:15pm - 12:35pm
Enhanced Bioprocess Efficiency for Biologics Production using OmniBRx Dynamic-Bed Reactor Technology
- Jiten Pant - CEO and CSO, OmniBRx Biotechnologies Inc
12:35pm - 12:55pm
Functional Assays at the Single Cell Level
- Robin Krueger - Vice President, Arralyze LPKF
12:55pm - 1:05pm
An Improved Method for the Characterization of Ultrafiltration (UF) Membranes for Bioprocessing
- Thomas Lazzara, PhD - Director, Research & Development, Meissner
1:05pm - 1:25pm
Leveraging Continuous Manufacturing to Expand Global Access to Biotherapeutics
- Ben Castro - SVP, Manufacturing Operations, Just – Evotec Biologics
Showing 9 of 9 Streams
Cell Culture & Upstream Processing - Room 210C
Recovery & Purification - Room 210B
Manufacturing Strategy & Bioprocessing 4.0 - Room 210A
Analytical & Quality - Room 209
Well Characterized Biologics & Biological Assays - Room 208
Cell Therapy Manufacturing - Room 206AB
Gene Edited Ex Vivo Manufacturing - Room 205C
In Vivo Gene Therapy Manufacturing - Room 205AB
BWB Main Stage
1:25pm - 1:30pm
Chairperson’s Remarks
- Christian Witz - CEO, SimVantage
1:30pm - 2:00pm
Leveraging AstraZeneca proprietary media platform to improve yield for a commercially approved NS0 derived therapeutic protein
- John Mavrianos - Associate Scientist V, Alexion Pharmaceuticals (AstraZeneca Rare Disease)
2:00pm - 2:30pm
More, Faster, Cheaper, Better in transient transfection
- Sowmya Balasubramanian - Senior Manager Process Development, Genentech
2:30pm - 3:00pm
Polymers for Biophamaceutical Applications
- Nadya Morales-Cummings, PhD - Global Technical Marketing Manager, BASF Corporation
1:25pm - 1:30pm
Chairperson’s Remarks
- Christopher Brown - Senior Director, Technical Operations, Tourmaline Bio, Inc
1:30pm - 2:00pm
Development of a Robust Workflow for Continuous UF/DF
- Brooke Elderbrock - Senior Research Associate, Sanofi
2:00pm - 2:30pm
Truly Continuous Affinity Capture Using Column-Free Affinity Ultrafiltration and Engineered Nanoparticles to Replace Protein A Chromatography
- Kareem Fakhfakh - Senior Scientist, Bioprocess Technologies and Engineering, AstraZeneca
2:30pm - 3:00pm
A fresh and innovative approach to addressing high aggregate challenges in engineered monoclonal antibodies
- Al de Leon - Manager, Thermo Fisher Scientific
1:25pm - 1:30pm
Chairperson’s Remarks
- Dhanuka Wasalathanthri, PhD - Senior Principal Scientist, Bristol Myers Squibb
1:30pm - 2:30pm
Panel Discussion: CDMO Selection and Partnering
- Ray Sison - Managing Partner at SCxCMC, SCmple
- Lisa Cozza - Principal Consultant; Culture Change Leader, Biopharma CMC, Commercial Readiness; Tunnell Consulting
- Justin Koepsel - Senior Director of Commercial Operations, Catalent Biologics
- J.D. Mowery - President & CEO, KBI Biopharma
2:30pm - 3:00pm
Next Generation Bioprocessing strategies to improve speed, cost and quality of tech transfer
- Marc Smith - Director of Strategic Solutions, IDBS
1:25pm - 1:30pm
Chairperson’s Remarks
- Anirban Adhikari - Global Technical & CMC Director (Analytical Development), Lonza
1:30pm - 2:00pm
SEC in tandem with MS: A Powerful Tool to Understand HCP Risk
- Younghoon Oh - Scientist, Janssen R&D
2:00pm - 2:30pm
Pros and Cons of Mass Spec for HCP Analysis
- Kevin Van Cott - Associate Professor, University of Nebraska-Lincoln
2:30pm - 3:00pm
Valita Aggregation Pure, A High-throughput, protein aggregation screening tool for bioprocessing
- Anna Boland - Product Development Scientist, ValitaCell HQ (part of Beckman Coulter Life Sciences)
1:25pm - 1:30pm
Chairperson’s Remarks
- Jeffrey Baker - Senior Fellow, NIIMBL; Strategic Advisor, CBI-MIT
1:30pm - 2:00pm
Phase Appropriate DP Development and Characterization in Relation to Human Clinical Trials
- A DP development roadmap defines the appropriate level of characterization ensuring safety, quality and potency in relation to the phase of the Human Clinical Trials
- Solution characterization together with clinical and pharmacy input will define the proper handling of the drug product at the clinical sites
- It is important to define the appropriate level of characterization in relation to the phase of clinical trials, not too little and not too much.
- Bruce Kerwin, Ph.D. - Member of Coriolis Scientific Advisory Committee, Kerwin Biopharma Consulting LLC
2:00pm - 2:30pm
Update on Method Qualification Vs. Phase Appropriate Method Validations
- Nadine Ritter, Ph.D. - President and Analytical Advisor, Global Biotech Experts, LLC
2:30pm - 3:00pm
Doubling Process Productivity and Speeding Up Process Development with Mechanistic Modeling for Chromatography
- Per Lidén - General Manager, GoSilico, Cytiva
1:25pm - 1:30pm
Chairperson’s Remarks
- Amish Patel - SVP Technical Operations, Calidi Biotherapeutics
1:30pm - 2:00pm
Novel Analytical Technologies for Cell Therapy Product Characterisation Strategies
- Lara Lonescu Silverman, PhD - Principal Consultant, LIS BioConsulting
2:00pm - 2:30pm
A new Method of Manufacturing for Fast & Reliable Discovery of Safe TCRs with Tunable Antigen Specificity
- Cameron Gardner - Director of Research Development, Jura Bio
2:30pm - 3:00pm
Ensuring High Purity Cell Therapy Products: A Focus on Accurately Characterizing Cell Aggregates, Residual Dynabeads, and Other Product Impurities
- Karessa White - Field Application Scientist, Halo Labs
1:40pm - 1:45pm
Chairperson's Opening Remarks
1:45pm - 2:00pm
A Tale of Two Cultures: The possibility to use the CliniMACS Prodigy® Platform for Allogeneic Cell therapy research processes
- Nicolas Danzenbächer - Clinical Marketing Manager, Miltenyi Biotec
2:00pm - 2:30pm
Scalable Production of human iPSCs in an Automated Bioreactor System for Bioprinting Applications
- Mark Skylar Scott, PhD - Associate Professor of Bioengineering, Stanford University, Stanford University
2:30pm - 3:00pm
Streamlining Therapeutic Development with Scalable Electroporation
- Joseph Abad - Senior Director, Process Development and Innovation, MaxCyte
1:25pm - 1:30pm
Chairperson’s Remarks
- Rajeev Boregowda - Associate Director, Bioassay & Molecular Analytical Development, Genomic Medicine CMC, Sanofi
1:30pm - 2:00pm
Optimization of Transfection Kinetics for the Production of Recombinant Adeno Associated Viral Vectors
- Dah-ve Bell - Scientist, Gene Delivery Process and Analytical Development, Bristol Myers Squibb
2:00pm - 2:30pm
Optimizing Ambr Cell Culture Process as the Scale-Down Model for AAV Production by Transient Transfection
- Nikki VanOstrand - Engineer in Cell Culture Development in Gene Therapy, Biogen
2:30pm - 3:00pm
Simplify and Accelerate the Path to Viral Vector Manufacture with the VirusExpress® LV and AAV Production Platforms
- Joe Orlando, Ph.D. - R&D Director, Life Science Services, MilliporeSigma
1:25pm - 1:30pm
Chair Opening Remarks
- Jared Auclair, PhD - Vice Provost Research Economic Development, Director of Bioinnovation, College of Science at Northeastern University
1:30pm - 2:20pm
Panel Discussion: Future Talent Structures that Inspire Inclusion and Cultivate a Winning Culture – A Call to Action to Achieve Diversity and Inclusion Today
- Karen Lewis - Chief People Officer, Apellis Pharmaceuticals
- Kenn Turner - President and CEO, Massachusetts Life Sciences Center
- Tamicka James - Senior Director and Head of Diversity and Inclusion, US Commercial, Medical, Government Affairs, Genentech
- Erin Cowhig - Chief People Officer, Nimbus Therapeutics
- Tricia McCall - Chief People Officer, Delix Therapeutics
2:20pm - 2:25pm
5 Minute Break
2:25pm - 3:00pm
[2:25-3:15] Imagine Our World: Creating Impact in the Biotechnology Industry
- Azurii Collier - President & Board Chair, Women in Bio, Director, Portfolio Innovation, Abbvie
Showing 3 of 3 Streams
Break
BWB Main Stage
Investor Forum - 104B
3:00pm - 4:00pm
Afternoon Break in the Exhibit & Poster Hall
3:00pm - 3:15pm
[2:25-3:15] Imagine Our World: Creating Impact in the Biotechnology Industry - Continued
- Azurii Collier - President & Board Chair, Women in Bio, Director, Portfolio Innovation, Abbvie
3:15pm - 3:20pm
5 Minute Break
3:20pm - 3:40pm
Laboratory Challenges for Radiation Sterilization Validation and Dose Audit Testing of Bioprocessing Products
- Jason Rogers - Principal Scientist, STERIS
3:40pm - 3:50pm
Tune into your Formulation: Rapid at/in-line Accurate Quantitation of Excipients and Protein Titer using High Precision Tunable Laser Spectroscopy (HPTLS™)
- Bryan Hassell, PhD - Founder / Chief Technology Officer, Nirrin Technologies
3:50pm - 4:00pm
Harnessing the Power of the Mobius® Breez Microbioreactor to Address Cell Therapy Process Optimization Challenges
- Kara Levine - Senior R&D Manager, Cell Therapy Applications, MilliporeSigma
3:30pm - 4:00pm
Investor Forum
- Andrew Lee - Principal, Northpond Ventures
- Nick Furtrell - Associate, Northpond Ventures
- John Ho - Principal, NIRRIN Analytics
- Lynne Frick - CEO, Cell X Technologies, Inc. & Co-Executive Director, BioInnovation Group, BioGuides LLC & BioInnovation Group
Showing 9 of 9 Streams
Cell Culture & Upstream Processing - Room 210C
Recovery & Purification - Room 210B
Manufacturing Strategy & Bioprocessing 4.0 - Room 210A
Analytical & Quality - Room 209
Well Characterized Biologics & Biological Assays - Room 208
Cell Therapy Manufacturing - Room 206AB
In Vivo Gene Therapy Manufacturing - Room 205AB
BWB Main Stage
Investor Forum - 104B
4:00pm - 4:30pm
Establishing comparability between fed-batch and intensified perfusion: Journey from batch to integrated continuous commercial biomanufacturing process
- Christopher Hwang - Chief Technology Officer, Transcenta Therapeutics, Inc
4:30pm - 5:00pm
Perfusion Technology Development – Scale-up from Bench to Pilot
- J.Alex Gadberry - Scientist, Bioprocess Technologies & Engineering, AstraZeneca
5:00pm - 5:30pm
Bioprocess Walk-Up Solutions - A streamlined interface and dedicated workflows with automated sample preparation and LC-MS analytics
- Mark Wrona - Consulting Scientist, Waters Corporation
4:00pm - 4:30pm
Key Learnings from N-mAb Case Study
- Gene Schaefer, Ph.D. - Senior Fellow, NIIMBL
4:30pm - 5:00pm
Continuous virus filtration for monoclonal antibody production
- Joshua Peles - Doctoral Student, Penn State University
5:00pm - 5:30pm
Fiber chromatographic enabled process intensification increases monoclonal antibody (mAb) product yield
- Sean Anderson, PhD - Bioprocess Applications Specialist, 3M, Separation and Purification Sciences, USA
4:00pm - 4:30pm
Biologics Approval & Accelerated Pathways in China
- Helen Ye - Regulatory Affairs Director, Accestra Consulting
4:30pm - 5:00pm
Measurement of Particulates in Single-Use Systems for Cell and Gene Therapies Manufacturing - Part 2
- Andreas Hohenleutner - Head of Operations, Characterization and Device services, Small Molecule Services, Solvias
- Joseph St.Laurent - Head of Industry Relations & Regulatory Expert, Solvias
- James Dean Vogel - Founder and Director , The BioProcess Institute
5:00pm - 5:30pm
A flexible, scalable, high-performance Single-Use Bioreactor designed to support intensified bioprocessing
- Samantha Whitney - Applications Engineer, MilliporeSigma
4:00pm - 4:30pm
Proteomics Supported Process Development for Bridging Host Cell Proteins Coverage Gap
- Ujjwal Bhaskar, Ph.D. - Associate Director, Bristol Myers Squibb
4:30pm - 5:00pm
Characterization and Clearance of Host-Cell-Protein-Rich Aggregates in Monoclonal Antibody Bioprocessing
- Chase Herman, Ph.D. - Investigator, GSK
5:00pm - 5:30pm
Deliver Products to Patients Faster with a Purpose-Built, No-Code EBR and MES
- Matt Lowe - Chief Strategy Officer, MasterControl
4:00pm - 4:30pm
Analytical Standards in the Characterization of Biopharmaceuticals
- Michael Tarlov - Chief, NIST
4:30pm - 5:00pm
NISTmAb and beyond: Standards support biotechnology and biomanufacturing innovation
- John Schiel, Ph.D. - Research Chemist, IBBR, National Institute of Standards and Technology
5:00pm - 5:30pm
USP Biologic Standards: Solutions for an Evolving Industry
- John Kokai-Kun - Director, Biologics Industry Collaborations and Partnerships, United States Pharmacopeia (USP)
4:00pm - 4:30pm
Control of Visible Particulates in Cell and Gene Therapies
- Kenneth Green, PhD - Snr Dir MSAT, Vertex
4:30pm - 5:00pm
Current Approaches and Considerations for Viral Clearance in Cell and Gene Therapy
- Sanjay Nilapwar - Principal Scientist, Abbvie
5:00pm - 5:05pm
Please Move to In Vivo Gene Therapy Track Room 205AB for the Closing Plenary Talk
4:00pm - 4:30pm
Gene Therapy Upstream Process Intensification and Platform Improvements from Ultragenyx
- Jun Li - Associate Director, Upstream Process Development, Gene Therapy, Ultragenyx Pharmaceutical
4:30pm - 5:00pm
High-Yield Recombinant Adeno-Associated Virus Vector Production by Multivariate Optimization of Bioprocess and Transfection Conditions
- Louis Coplan - Process Development Engineer, Viral Production Core, Regeneron Pharmaceuticals, Inc.
5:00pm - 5:20pm
Closing Plenary: Tribulations to Trials: Bench-to-Bedside CDMOs
- Rona Singer Weinberg, PhD - Founding Scientist, Cell Therapy Laboratory, Comprehensive Cell Solutions
4:00pm - 4:20pm
Supply Chain Management
- Joe Ivan - Head of Supply Chain Services, DS InPharmatics, a ProductLife Group Company
4:20pm - 4:30pm
Paving the way to Affordable and Accessible Advanced Therapies: Innovation in Bioprocess Technologies for ATMP Manufacturing
- René Gantier, PhD - Senior Director R&D, Advanced Bioprocess Applications, Repligen
4:30pm - 4:35pm
5 Minute Break
4:35pm - 5:25pm
Lessons in Diversity, Equity and Inclusion: For Teams and Individuals to Thrive
- Chaunté Lowe - Motivational Olympic Medalist, American Record Holder, and TEDx Speaker, USA
4:00pm - 5:00pm
Investor Forum
- John Ho - Principal, NIRRIN Analytics
- Andrew Lee - Principal, Northpond Ventures
- Nick Furtrell - Associate, Northpond Ventures
5:30pm - 9:00pm
Biotech Week Boston Festival Party @ Lawn on D
Get the Latest Event Updates
Sign up to get the latest event updates and information.
Filter
Streams